Biosearch Technologies Executes Exclusive License for turboFISH™
PETALUMA, CA (Monday, October 7, 2013) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry announced today that it has acquired exclusive worldwide rights to turboFISH technology - A Method for Rapid Single Molecule RNA FISH. With this turboFISH license, Biosearch maintains exclusive access to continuing Stellaris® RNA FISH based inventions from Rutgers, The State University of New Jersey.
Co-inventor, Arjun Raj, now an assistant professor at the University of Pennsylvania states, "We are very excited about the possibilities that ultra rapid RNA FISH opens up, particularly in diagnostic applications. Being able to perform a protocol in 5 minutes (or sometimes as little as 30 seconds) with virtually no loss in signal integrity marks a huge shift in our conception of what one can do with RNA FISH."
“Point of Care, point of contact, hospital bedside and immediate care facilities are now target markets for real-time gene expression analysis using turboFISH,” comments Marc Beal, Director of Corporate Development and Licensing at Biosearch. “Extending turboFISH into the OR for intraoperative analysis may allow for real-time cancer diagnostics, eliminating the need, ambiguities and procedure of formalin fixation and paraffin embedding tissues for days later analysis.”
About Biosearch Technologies, Inc.
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 and ISO 13485:2003 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR, Stellaris RNA FISH, and other genomic-based applications.
In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and in the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 3003009052), and licensed by the State of California Department of Public Health (license number 72147) as a medical device manufacturer. As such, its GMP and Commercial Services manufacturing processes conform to all applicable requirements per 21 CFR Part 820 and ISO 13485:2003. Biosearch’s markets include pharmaceutical, in vitro diagnostics, biotechnology, ag/bio, environmental and food testing, public health, and biodefense sectors.
Established in 1766, Rutgers, The State University of New Jersey, is America's eighth oldest institution of higher learning and one of the nation's premier public research universities, serving more than 65,000 students on campuses, centers, institutes and other locations throughout the state.
Rutgers Biomedical and Health Sciences is the health care education, research, and clinical division of Rutgers University, comprising nine schools and their attendant faculty practices, centers, institutes and clinics, including the Public Health Research Institute.
For additional information about Rutgers please visit www.rutgers.edu.